CV Science

Benoît Ho-Tin-Noé PhD Pathophysiology and Cell Biology

Course and current status

2023-Present                Team leader at INSERM Unit 1144, OTEN Laboratory, Paris Faculty of Pharmacy, Paris Cité University, France.

2009-2022                CRCN at INSERM Unit 698/1148, Laboratory for Vascular Translational Science, Bichat Hospital, Paris, France.

2006-2008                      Postdoctoral fellow at The Wagner Lab, Immune Disease Institute, Department of Pathology, Harvard Medical School, Boston, MA, USA.

2002-2005                                            PhD Pathophysiology and Cell Biology at INSERM Unit 698 “Cardiovascular Remodeling”,

Université Paris VII Denis Diderot, Paris, FRANCE.

1999-2002                                         Master of Science (Summa cum Laude), Vascular Cell Biology and Physiology, Université Paris VII Denis Diderot, Paris, FRANCE.

1997-1999                      Bachelor of Science (Cum Laude), Cell Biology, Université Paris VII Denis Diderot, Paris, FRANCE.

Scientific summary

After completing a PhD in Hemostasis and Vascular Biology (Paris Diderot University) during which he studied the mechanisms of cellular plasminogen activation, B. Ho-Tin-Noé joined the laboratory of Dr Denisa Wagner (HMS, Boston) in 2006 , where he worked for 3 years as a postdoctoral fellow. There, he initiated a series of studies on the role of platelets in the maintenance of vascular integrity in inflamed organs and solid tumors. He was then recruited in 2009 as a tenured researcher by the French National Institute of Health & Medical Research (INSERM) to work in a cardiovascular research academic laboratory in Paris (The Laboratory for Vascular Translational Science). After 3 years as a junior investigator, he founded his research group in 2012. He joined the OTEN Laboratory (Therapeutic Optimization in Neuroparmacology) at the Paris Faculty of Pharmacy in  2022 to found a new INSERM research team together with Pr Mikael Mazighi. This team studies how thromboinflammation contributes to the pathophysiology of thrombotic and cerebrovascular diseases and aims at optimizing the efficacy and safety of thrombolytic and antithrombotic therapies.